Drug intelligence / Profile preview

MEG-B-09

Development stage: Unknown
Administration: Oral

Overview

MEG-B-09 is a pharmaceutical product that has been studied under the combination name ABO/MEG-B-09 for use in children with acute cough. Its precise composition, mechanism of action, and pharmacological classification have not been explicitly detailed in the available literature or clinical trial records. It is described as a "syrup" formulation for pediatric use, but no molecular or chemical description is available from authoritative sources.

Brand names: MEG-B-09MEG-B09MEG-B 09
Other names: MEG-B-09MEG-B09MEG-B 09

Beyond the preview

Go deeper on MEG-B-09.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEG-B-09.

Explore the full profile